Table 2.
Clinical Characteristics of Study Participants in MTUTH, South West Ethiopia, 2007–2017
| Variables | Category of Variables | N (%) | Status | |
|---|---|---|---|---|
| Censor | Death | |||
| N (%) | N (%) | |||
| CD4 count | <200 | 124 (34.1) | 51 (41.1) | 73 (58.9) |
| ≥200 | 240 (65.9) | 230 (95.8) | 10 (4.2) | |
| ART regimen | First line | 343 (94.2) | 267 (77.8) | 76 (22.2) |
| Second line | 21 (5.8) | 14 (66.7) | 7 (33.3) | |
| Use of CPT | Yes | 283 (77.7) | 238 (84.1) | 45 (15.9) |
| No | 81 (22.3) | 43 (53.1) | 38 (46.9) | |
| OIs other than TB | No at all | 105 (28.8) | 93 (88.6) | 12 (11.4) |
| One or two | 232 (63.7) | 175 (75.4) | 57 (24.6) | |
| At least three | 27 (7.4) | 13 (48.1) | 14 (51.9) | |
| ART failure history | Yes | 21 (5.8) | 14 (66.7) | 7 (33.3) |
| No | 343 (94.2) | 267 (77.8) | 76 (22.2) | |
| Functional status | Working | 139 (38.2) | 126 (90.6) | 13 (9.4) |
| Ambulatory | 149 (40.9) | 137 (91.9) | 12 (8.1) | |
| Bedridden | 76 (20.9) | 18 (23.7) | 58 (76.3) | |
| WHO clinical stages | One | 60 (16.5) | 51 (85) | 9 (15) |
| Two | 51 (14) | 46 (90.2) | 5 (9.8) | |
| Three | 220 (60.4) | 167 (75.9) | 53 (24.1) | |
| Four | 33 (9.1) | 17 (51.5) | 16 (48.5) | |
Abbreviations: ART, anti retroviral therapy; CPT, cotrimoxazole preventive therapy; CD4, Cluster of differentiation four; TB, tuberculosis; OIs, opportunistic infections; BMI, body mass index; WHO, World Health Organization.